These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 27024483)

  • 1. Rethinking cholesterol management. Lowering LDL levels is once again the Holy Grail, since raising HDL failed to make a difference after all.
    Duke Med Health News; 2013 Mar; 19(3):3. PubMed ID: 27024483
    [No Abstract]   [Full Text] [Related]  

  • 2. LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. A lesson from cholesterol turnover studies and others.
    Sirtori CR; Fumagalli R
    Atherosclerosis; 2006 May; 186(1):1-11. PubMed ID: 16310198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-density lipoprotein cholesterol as the Holy Grail.
    Cannon CP
    JAMA; 2011 Nov; 306(19):2153-5. PubMed ID: 22089726
    [No Abstract]   [Full Text] [Related]  

  • 4. Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials.
    Kühnast S; Fiocco M; van der Hoorn JW; Princen HM; Jukema JW
    Eur J Pharmacol; 2015 Sep; 763(Pt A):48-63. PubMed ID: 25989133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDL cholesterol: is higher really better? Raising HDL with niacin takes a back seat to lowering LDL with statins.
    Harv Heart Lett; 2012 Mar; 22(7):4. PubMed ID: 27024344
    [No Abstract]   [Full Text] [Related]  

  • 7. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LDL-cholesterol as a determinant of coronary heart disease.
    Hunninghake D
    Clin Ther; 1990; 12(5):370-5; discussion 369. PubMed ID: 2268861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordance between non-HDL cholesterol and LDL cholesterol levels in patients with diabetes without previous cardiovascular events.
    Idris I; Al-Ubaidi F
    Diabetes Metab; 2010 Sep; 36(4):299-304. PubMed ID: 20537932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New insights and perspectives in the management of dyslipidemia].
    Cohen Aubart F; Hansel B; Hulot JS; Lechat P; Bruckert E
    Rev Med Interne; 2007 Aug; 28(8):537-44. PubMed ID: 17337099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cyclic estrone sulfate treatment on lipid profiles of postmenopausal women with elevated cholesterol levels.
    Notelovitz M; Katz-Karp S; Jennings D; Lancaster J; Green EM; Stoll RW
    Obstet Gynecol; 1990 Jul; 76(1):65-70. PubMed ID: 2193271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of triangle drugs as ginseng, Trichosanthes kirilowii maxim and rhubarb on the level of blood lipids and related pro-inflammatory cytokines during the process of treating atherosclerosis].
    Wang JY; Wu SX; Jiang LD
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 May; 31(5):667-71. PubMed ID: 21812271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gemfibrozil in the differential therapy of disorders of fat metabolism].
    Ebner F
    Fortschr Med; 1992 Oct; 110(28):523-6. PubMed ID: 1398412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid.
    Schachter M
    Cardiovasc Drugs Ther; 2005 Dec; 19(6):415-22. PubMed ID: 16453091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The place of HDL in cholesterol management. A perspective from the National Cholesterol Educational Program.
    Grundy SM; Goodman DW; Rifkind BM; Cleeman JI
    Arch Intern Med; 1989 Mar; 149(3):505-10. PubMed ID: 2645842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.